BridgeMD
Study of BLU-808 in Chronic Inducible Urticaria and Chronic Spontaneous Urticaria
EU CTIS ID: 2024-520031-33-00
What this study is testing
Part A/B: To characterize the safety and tolerability of BLU-808
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Part A: Confirmed diagnosis of chronic inducible urticaria for ≥3 months prior to Day 1 that is inadequately controlled with second generation H1-antihistamines
- 2. Part B: Confirmed diagnosis of chronic spontaneous urticaria for ≥3 months prior to Day 1 that is inadequately controlled with second generation H1-antihistamines
- 3. Other protocol-defined criteria apply
You likely can't join if
- 1. Part A: Any active urticaria that may interfere with study assessments
- 3. Part B: Participant has a clearly defined predominant cause of chronic urticaria or sole trigger such as symptomatic dermographism and cold-induced urticaria
- 4. Part A/B: Any other skin disease associated with chronic itching, angioedema, or that might influence the study evaluations and results, skin diseases associated with only wheals and no itch, or autoinflammatory diseases with urticarial lesions
- 5. Part A/B: Significant medical, psychiatric, or surgical conditions, or physical findings that may affect participant safety, study drug metabolism, study participation, or assessment of study results
- 6. Part A/B: Abnormal laboratory values that may pose risks or interfere with study participation
- 7. Part A/B: Pregnancy or plans for pregnancy; breastfeeding
See the full eligibility criteria
- 1. Part A: Confirmed diagnosis of chronic inducible urticaria for ≥3 months prior to Day 1 that is inadequately controlled with second generation H1-antihistamines
- 2. Part B: Confirmed diagnosis of chronic spontaneous urticaria for ≥3 months prior to Day 1 that is inadequately controlled with second generation H1-antihistamines
- 3. Other protocol-defined criteria apply
- 1. Part A: Any active urticaria that may interfere with study assessments
- 3. Part B: Participant has a clearly defined predominant cause of chronic urticaria or sole trigger such as symptomatic dermographism and cold-induced urticaria
- 4. Part A/B: Any other skin disease associated with chronic itching, angioedema, or that might influence the study evaluations and results, skin diseases associated with only wheals and no itch, or autoinflammatory diseases with urticarial lesions
- 5. Part A/B: Significant medical, psychiatric, or surgical conditions, or physical findings that may affect participant safety, study drug metabolism, study participation, or assessment of study results
- 6. Part A/B: Abnormal laboratory values that may pose risks or interfere with study participation
- 7. Part A/B: Pregnancy or plans for pregnancy; breastfeeding
- 8. Other protocol-defined criteria apply
The study team makes the final eligibility decision.
Where it's taking place
- Taiwan
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Taiwan; United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.